ArticleJournal of cancer research and clinical oncology2026
Sensitivity and prognostic significance of circulating tumor DNA (ctDNA) in stage I to III malignant melanoma.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRisk stratification to guide adjuvant treatment in early stages of melanoma becomes increasingly important. This study investigated circulating tumor (ct)DNA in early melanoma stages to predict disease progression in real-world settings in German melanoma patients.
methodsIn this retrospective, single-center study, 61 patients with melanoma stages I-III with known disease-progression following primary diagnosis were included. Patients were requested to have baseline serum samples ≤ 4 weeks after diagnosis and ≥ 12 weeks preceding disease progression. In ctDNA isolated from 185 serum samples matching inclusion criteria, BRAF V600E/K, NRAS Q61K/L/R and TERT promoter mutations were quantified and correlated with serum levels of S100 and LDH.
resultsMutated ctDNA was detected in ≥ 1sample in 43 of 53 patients (81.13%). CtDNA was more sensitive in the prediction of melanoma relapse than established biomarker S100, LDH (p < 0.001) and both LDH/S100 (p < 0.001). Highest mean ctDNA was measured during shift of stage III to stage IV disease (24.25 cps/µL) and shift within stage III (12.42 cps/µL). The detection of ctDNA at any time point trended towards shorter overall survival.
conclusionOur study demonstrates the superiority of ctDNA harboring melanoma specific mutations over LDH and S100 in identifying patients at risk for recurrence in early melanoma stages in a single center cohort of melanoma patients. Future prospective trials are warranted to confirm this.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.